Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPI-001 in Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
NCT07716865Phase 2Active, not recruiting
- Sponsor
- Arctic Therapeutics
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of N-acetylcysteine amide in Hereditary cystatin C amyloid angiopathy (HCCAA), sponsored by Arctic Therapeutics. Started Apr 2024; status: active, not recruiting.
02
Drugs
N-acetylcysteine amide
03
Conditions
Hereditary cystatin C amyloid angiopathy (HCCAA)
Beyond the preview
Go deeper on NCT07716865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07716865.